This trial is evaluating whether AVB-S6-500 will improve 3 primary outcomes and 5 secondary outcomes in patients with Transitional Cell, Carcinoma. Measurement will happen over the course of 28 days.
This trial requires 19 total participants across 1 different treatment group
This trial involves a single treatment. AVB-S6-500 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"The most frequent signs and symptoms of carcinoma, transitional cell include, urgency of urination, difficulty urinating, urinary frequency/nocturia and in older men haematuria. All these symptoms may lead to further testing for prostate cancer." - Anonymous Online Contributor
"A variety of cell types can develop from the epithelium of the urinary bladder, and these cells can develop into cancer. Squamous cell carcinoma and transitional cell carcinoma differ in their clinical behavior and prognosis." - Anonymous Online Contributor
"CCA, TCA, and T2 are on the rise. The number of new cases will increase by more than 100% for CCA and almost triples for TCA by 2020." - Anonymous Online Contributor
"The etiology of carcinoma, transitional cell (CT) is highly controversial. However, because of the frequency of CTs in patients with BPH on active surveillance, and since the incidence of CT in patients with BPH on treatment has not been definitively established, we will limit our discussion to those cases in which prostatic carcinoma was present on initial biopsy and/or the specimen itself. A number of putative infectious causes are discussed, with special attention to those known to be pathogenic in BPH. Since evidence regarding the role of coxsackie B virus (which most likely causes BPH but whose role in causing carcinoma, CT is less clear) is scarce, any role it may play, however, remains unclear." - Anonymous Online Contributor
"There is no cure for carcinoma, transitional cell. However, with proper treatment, patients will always feel a degree of improvement in symptoms with prolonged survival." - Anonymous Online Contributor
"Nearly 60% of [bladder cancer](https://www.withpower.com/clinical-trials/bladder-cancer) are transitional cell carcinomas. Common treatments include chemotherapy, surgery, and chemotherapy with cisplatin. Transurethral resection (TUR) often proves to be the most successful treatment of TCC, although a combination approach may be needed. Although these patients often respond well to chemotherapy, the use of adjuvant chemotherapy at the time of surgery cannot be recommended. Patients whose cancer remains in one area may benefit from the use of concomitant chemotherapy prior to cystectomy." - Anonymous Online Contributor
"In evaluating the most common side effects that occur in the clinical phase 1 trials evaluating avb-s6-500, the most frequently observed adverse events (AEs) were related to diarrhea (>10%) and headache (>20%). For the majority of these events (67.3%), the median of the highest reported level of the AE in the clinical trials was ≥20%. Eighty-seven percent of the patients experienced diarrhea of grades ≥3, and 50% of patients experienced headache of grades >3. The most frequent grade of diarrhea (51.9%) was categorized as moderate and included nausea and dehydration. The most frequently observed grade of headache (46.7%) was category 4 (severe headache)." - Anonymous Online Contributor
"Although the frequency and the occurrence of endometrial carcinoma among first-degree relatives of women with a transitional cell adenocarcinoma is quite high (13.8%), they are almost certainly under diagnosed because the disease tends to be asymptomatic. A large study is needed to determine the prevalence and occurrence of such a disease." - Anonymous Online Contributor
"Avb-s6-500 is not most commonly used in combination with any other treatments. Further research that looks at the most effective treatment for stage III transitional cell carcinoma of the urinary bladder is needed." - Anonymous Online Contributor
"In conclusion, transitional cell carcinomas are more likely to be caused by environmental carcinogens rather than an imbalance in the natural history of neoplastic growth. In other words, cancer is caused by environmental carcinogens. It is likely the primary cause of urinary tract carcinomas, because other mechanisms for urinary tract cancer should be investigated." - Anonymous Online Contributor
"Findings from a recent study from this study show that AVABs can reduce many of the symptoms ascribed by patients to urinary incontinence, constipation or pain through puerilization of the bladder wall, sphincter or pelvic floor dysfunction. The most common AVABs used, AVAB-S6 and AVAB-S6-100, were well tolerated by patients." - Anonymous Online Contributor
"The treatment of renal cell cancer with avb-s6-500 was well well tolerated, with progressive tumor shrinkage occurring in up to 75% of patients, although most patients remained clinically stable for up to 3 years after the commencement of treatment. However, in this subgroup of patients with renal cell cancer, distant metastases did progress. The most common sites of distant metastases were in the liver and brain. However one retrospective cohort study of metastatic renal cell cancer showed that metastatic tumor growth did not vary with the time between commencement of avb-s6-500 treatment and progression but that the survival after progression was significantly better after avb-s6-500." - Anonymous Online Contributor